Loading stock data…
Omeros Corporation (OMER)
$9.91+1.24 (+14.30%)
After Hours$9.71-0.20 (-2.02%)· Last close Jun 29
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omeros Corporation in the Healthcare sector is trading at $9.91 with a market capitalization of $648M. Wall Street consensus targets $33.00 (1 analysts), implying a +233.0% move over the next 12 months. The stock is currently 44% below its 52-week high of $17.65, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +233.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.89M | $0 | $0 | $0 | $0 |
| Gross Profit | $9.31M | — | — | — | $0 |
| Operating Income | -$17.42M↑ | -$29.08M↓ | -$26.39M↑ | -$32.35M↑ | -$34.97M |
| Net Income | $56.06M↓ | $86.45M↑ | -$30.92M↓ | -$25.42M↑ | -$33.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narso...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$648.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-136.06%
Volume
Today's trading volume
2.74M
Recent News
Why Is OMER Stock Falling Today?
European regulators issued a negative opinion on Yartemlea, Omeros’ therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now
Omeros (OMER) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Omeros (OMER) Q1 2026 Earnings Transcript
Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. After that, David will cover the financials in more detail and then we'll open the call for questions.